Black Diamond Therapeutics Inc reports results for the quarter ended in September - Earnings Summary

Black Diamond Therapeutics

08/11/2022 14:30

* Black Diamond Therapeutics Inc  BDTX.OQ  reported a
quarterly
adjusted loss of 60 cents​​ per share for the quarter ended in
September. The mean expectation of five analysts for the quarter
was for a loss of 64 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Black Diamond Therapeutics Inc's reported EPS for the
quarter
was a loss of 60 cents​.
    * The mean earnings estimate of analysts had risen by
about 2.4%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Black Diamond Therapeutics Inc shares had risen by 30.8%
this
quarter and lost 58.5% so far this year.
    * The company reported a quarterly loss of $21.65 million.
    * Wall Street's median 12-month price target for Black
Diamond
Therapeutics Inc is $4.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
8 at 02:30 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -0.64          -0.60          Beat
 Jun. 30 2022      -0.68          -0.63          Beat
 Mar. 31 2022      -0.75          -0.70          Beat
 Dec. 31 2021      -1.01          -0.71          Beat